Melissa Terry
Psychiatric/Mental Health · Wabash, INNPI 1083255855
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 443 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 443 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Sunovion Pharmaceuticals Inc.$910
- Lundbeck LLC$675
- AbbVie$593
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$529
- Teva Pharmaceuticals USA, Inc.$491
- plus $3K from 21 others
What the payments were for
- Food & beverage$6,72696%
- Education$2504%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 48 | $1,049 |
| Sunovion Pharmaceuticals Inc. | 48 | $910 |
| Lundbeck LLC | 87 | $675 |
| AbbVie | 47 | $593 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $529 |
| Teva Pharmaceuticals USA, Inc. | 25 | $491 |
| Alkermes, Inc. | 23 | $430 |
| Neurocrine Biosciences, Inc. | 18 | $372 |
| E.r. Squibb & Sons, L.L.C. | 15 | $302 |
| Vanda Pharmaceuticals Inc. | 19 | $277 |
| Supernus Pharmaceuticals, Inc. | 12 | $231 |
| Corium, LLC | 16 | $170 |
| Biogen | 9 | $146 |
| Johnson & Johnson | 8 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $134 |
| Axsome Therapeutics, Inc. | 5 | $94 |
| Tris Pharma Inc | 5 | $88 |
| Collegium Pharmaceutical, Inc. | 3 | $63 |
| Merck | 4 | $56 |
| Ironshore Pharmaceuticals Inc. | 3 | $55 |
| Indivior Inc. | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Eisai Inc. | 2 | $30 |
| Exact Sciences | 1 | $20 |
| Gilead | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$125
How this compares
$6,976 in reported general payments places this provider in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 120 | $192,798 |
| Invega SustennaPaliperidone Palmitate | 59 | $178,076 |
| RexultiBrexpiprazole | 102 | $154,884 |
| AustedoDeutetrabenazine | 35 | $121,670 |
| Austedo XrDeutetrabenazine | 20 | $100,197 |
| Abilify MaintenaAripiprazole | 29 | $85,831 |
| CaplytaLumateperone Tosylate | 47 | $82,600 |
| TrintellixVortioxetine Hydrobromide | 118 | $70,072 |
| Lurasidone Hcl | 91 | $22,958 |
| BelsomraSuvorexant | 22 | $13,421 |
| VyvanseLisdexamfetamine Dimesylate | 26 | $11,482 |
| Aripiprazole | 85 | $9,514 |
| Paliperidone ErPaliperidone | 12 | $7,546 |
| Divalproex Sodium ErDivalproex Sodium | 56 | $7,436 |
| Ziprasidone Hcl | 54 | $7,364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,049 | $240,716131 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $491 | $221,86755 claims |
| AbbVieVraylar | $593 | $192,798120 claims |
| Johnson & JohnsonInvega Sustenna | $139 | $178,07659 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $529 | $82,60047 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $134 | $81,554144 claims |
| MerckBelsomra | $56 | $13,42122 claims |
| Eisai Inc.Dayvigo | $30 | $6,31720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Wabash
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
- Sharon ClevengerFort Wayne$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.